Three articles.

SANTA BARBARA, Calif., May 22 (Reuters) - Surgical and medical device company Inamed Corp. <IMDC.O> announced Tuesday that its second quarter sales were down 4.5 percent so far due to lower breast implant prices and weak collagen sales in Europe.

The Santa Barbara, Calif.-based company said second-quarter sales through mid-May 2001 were $31.3 million, down 4.5 percent from the prior year. On a year-to-date basis, sales were $89.1 million, 4.2 percent below the same period last year.

The company said second-quarter sales were following trends seen in the first quarter, with U.S. breast implant dollar sales down, while unit sales were up.

Outside the U.S., particularly in Europe, collagen sales continue to run behind the previous year, in part due to concerns relating to mad cow disease, the company said.

"However, our obesity products again showed very strong sales in the first half of the second quarter, consistent with the prior quarter. We look forward to adding to our obesity product sales, as we continue to expect FDA

(U.S. Food and Drug Administration) approval for the Lap-Band before the close of the second quarter. We remain confident of our excellent long-term growth prospects," Richard Babbitt, Inamed's chairman, said in a statement.

17:38 05-22-01

SANTA BARBARA, Calif.--(BUSINESS WIRE)--May 22, 2001--Inamed Corp. (Nasdaq: IMDC) today provided investors with a mid-quarter sales update for the second

quarter ending June 30, 2001.

Sales through mid-May 2001 were $31.3 million, down 4.5 percent from the prior year. On a year-to-date basis, sales were $89.1 million, 4.2 percent below the same period last year.

Commenting on the mid-quarter results, Richard G. Babbitt, Inamed's chairman and chief executive officer, said: "As in the first quarter, U.S. breast implant dollar sales are down, while unit sales are up, again due to a shift in mix. Outside the U.S., particularly in Europe, collagen sales continue to run behind the prior year, in part due to concerns relating to BSE.

"However, our obesity products again showed very strong sales in the first half of the second quarter, consistent with the prior quarter. We look forward to adding to our obesity product sales, as we continue to expect FDA approval for the Lap-Band before the close of the second quarter. We remain confident of our excellent long-term growth prospects."

Inamed is a global surgical and medical device company engaged in the development, manufacturing and marketing of products for the plastic and reconstructive surgery, aesthetic medicine and obesity markets. Inamed sells a variety of lifestyle products used to make people look younger and more attractive, including breast implants for cosmetic augmentation and collagen-based facial implants to correct facial wrinkles and to improve lip definition. Inamed also sells products that address women's health issues, including breast implants for reconstructive surgery following a mastectomy, and devices that treat severe obesity and urinary incontinence.

This release contains, in addition to historical information, forward-looking statements. Such statements are based on management's c rrent expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include but are not limited to those described in the company's annual report on Form 10-K for the year ended Dec. 31, 2000.

CONTACT:

Inamed Corp., New York

Michael Doty, SVP & CFO, 212/273-3430 (investors)

or

Citigate Sard Verbinnen, New York

11:35am 05/17/01 ATIS gains after seeking FDA approval (ATIS, IMDC) By Ted Griffith

Shares of Advanced Tissue Sciences rose sharply Thursday after the company said its partner Inamed Corp. filed for government marketing clearance to sell human-based collagen developed by Advanced Tissue Sciences. If approved, injections of the collagen would be used to reduce the appearance of facial wrinkles, according to the companies. Inamed had previously applied for U.S. Food and Drug Administration approval to sell collagen derived from cows. But in a statement Wednesday, Inamed said that it believes "many people will prefer to use this human-based collagen." Shares of Advanced Tissue Sciences